Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Core One Labs Inc C.COOL

Alternate Symbol(s):  CLABF

Healthcare Cannabis
Core One Labs Inc. is a Canada-based life sciences biotechnology research and development company. The Company is focused on bringing psychedelic medicines to market through the development and production of psychedelic compounds, the advancement of psychedelic assisted treatments, and the integration of delivery systems technology. Its subsidiary, Vocan Biotechnologies Inc., has developed and filed for patent protection of a proprietary psilocybin production system using engineered bacteria. It is also the holder of four provisional patents for the development of psychedelic-based pharmaceutical formulations targeting neurological and mental health disorders, under its subsidiary Akome Biotech Ltd., and three provisional patents under its other subsidiary, Awakened Biosciences Inc., for additional synthetic technologies for psilocybin and psilocin production methods. It also holds an interest in four medical clinics, which maintain a combined database of more than 275,000 patients.


CSE:COOL - Post by User

Core One Labs Inc > Webcast Aug 4
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1208)
•••
Comment by CancerSlayeron Aug 05, 2021 12:58pm
262 Views
Post# 33655332

RE:RE:Webcast Aug 4

RE:RE:Webcast Aug 4
CancerSlayer wrote:

Thanks...

Any updates given re: the status of that sublingual strip/transmucosal delivery patent?  Once/if granted, having rights/ownership to such a patent would potentially do wonders for their other proprietary drugs for which they've filed provisional apps (I.e. utilizing/crossing over to a more practical form of drug delivery for clinical trials, which would translate well for "real world" outpatient use).  

As far as I know, their original strip delivery patent process (invented by Dr. Sanderson) has been several years in the making now...still waiting.  I believe it had included at least one modified or 2nd provisional app being filed.  Let's hope these new provisional apps/future apps get filed as "non-provisional" apps in a more timely/less risky manner.  

By the way, does COOL still have rights/ownership of their first "pending" patent (the one for the strip technology)?  Is Dr. Sanderson even still involved with this company?  


 

Based on further review, it appears the company "does" have ownership/rights to the thin strip tech patent that is pending.  I would think we should hear news fairly soon re: a decision on patent approval....maybe this year?

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities